Etanercept in spondyloarthropathies. Part I: Current evidence of efficacy

C. Palazzi, S. D'Angelo, F. Cantini, E. Lubrano, A. Marchesoni, A. Mathieu, C. Salvarani, R. Scarpa, A. Spadaro, I. Olivieri

Research output: Contribution to journalArticlepeer-review


Etanercept is a recombinant soluble tumour necrosis factor alpha receptor administered subcutaneously at the dose of 50 mg weekly (or 25 mgltwice weekly) for the treatment of the main chronic arthritides: rheumatoid arthritis and spondyloarthropathies. It shows high qualities in terms of efficacy and manageability. Favourable results were reported in all localisations of spondyloarthropathies: axial disease, peripheral arthritis, and enthesitis. In particular, several studies demonstrated its efficacy on the clinical and functional indicators of ankylosing spondylitis. Similar data were also reported for psoriatic arthritis in which, in addition, a significant reduction in the progression of erosive damages was widely described. Furthermore, although only a few studies are available, very interesting results have been obtained in patients suffering from undifferentiated spondyloarthropathies and severe enthesitis.

Original languageEnglish
Pages (from-to)858-864
Number of pages7
JournalClinical and Experimental Rheumatology
Issue number5
Publication statusPublished - 2011


  • Ankylosing spondylitis
  • Efficacy
  • Etanercept
  • Psoriatic arthritis
  • Spondiloarthropathies

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Etanercept in spondyloarthropathies. Part I: Current evidence of efficacy'. Together they form a unique fingerprint.

Cite this